Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DSCAM drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DSCAM ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View DSCAM Products |
| Gene Delivery | DSCAM Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View DSCAM Products |
| Benchmark Ab | Anti-DSCAM Recombinant Antibody Recombinant positive control. |
View DSCAM Products |
| Validator | DSCAM siRNA Set For knockdown verification. |
View DSCAM Products |
| Related Target A | DSCAML1 Close homolog. Critical for off-target selectivity and counter-screening. |
View DSCAML1 Products |
| Related Target B | NTN1 (Netrin-1) Known ligand interacting with DSCAM; crucial for blocking/neutralization assays. |
View NTN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity. |
| Homolog counter-screening (DSCAML1) | DSCAML1 recombinant proteins strictly verified by mass spectrometry and high-resolution SDS-PAGE. |
| Lack of Clinical Controls | Clinical benchmark antibodies (biosimilars) included. |
| False Positives in Knockdown | Sequence-verified siRNA sets included for target knockdown specificity checks. |
Live DSCAM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Down Syndrome Cell Adhesion Molecule (DSCAM) is emerging as a novel frontier in oncology, particularly in breast, lung, and colorectal cancers where it is aberrantly overexpressed. Historically characterized for its role in axonal guidance, recent translational oncology has highlighted DSCAM as a viable target for Antibody-Drug Conjugates (ADCs) and targeted monoclonal antibodies (mAbs). As drug developers pivot toward addressing resistance to current HER2- or TROP2-targeted therapies, DSCAM represents an independent biomarker and therapeutic node with distinct internalization kinetics.
The race for DSCAM therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs and bispecific formats. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific extracellular epitopes that minimize neural toxicity while maximizing tumor-selective internalization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Academic & Biopharma Consortia | Breast Cancer, Osteosarcoma | Internalization Assay (Requires native glycosylated ECD-Fc fusion protein) |
| Monoclonal Antibody (mAb) | Early-Stage Biotech | Colorectal Cancer, Neurological Disorders | High-affinity binding & ligand-blocking screening (Requires DSCAM/Netrin-1 interaction validation) |
| Bispecific Antibody | Immuno-oncology Innovators | Solid Tumors | Heterodimer validation (Requires stable cell lines via Lentivirus) |